Oil Sinks 6%, Nasdaq 100 Rallies On Iran Talks: Stock Market Today

COHR Falls 17% in a Month: Is the Sell-Off an Opportunity?

Coherent Corp. shares declined 17% over the past month despite fiscal 2026 revenues rising 22.5% to $7.12 billion, driven by strong AI datacenter and communications demand. While the company shows robust demand visibility through 2028 and improving margins, investors are concerned about elevated execution risks from massive capital expenditures ($1.1B in fiscal 2026), declining operating cash flow, and overlapping product ramps. The stock trades at 26.5X forward earnings, above industry average, creating valuation concerns despite strong momentum.

8-K filing — APPLIED OPTOELECTRONICS, INC. (AAOI)

Filed: 2026-09-01 AccNo: 0001683168-26-006862 Size: 990 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

Jefferies Initiates Coverage On Almonty Indus with Buy Rating, Announces Price Target of $26.25

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.